GADx reintroduces IT-Leish, the rapid diagnostic test for visceral leishmaniasis

Packets of the IT-Leish rapid diagnostic test (RDT) for visceral leishmaniasis are displayed against a gradient background transitioning from teal to purple. Each white packet is clearly labeled with identification details including "IT LEISH", lot numbers, and expiration dates, along with the IVD (in vitro diagnostic) symbol, emphasizing their use in medical diagnostics. The packets are partially overlapped, focusing on their essential information and sterile packaging.

Global Access Diagnostics (GADx), a social enterprise prioritising equitable access to diagnostics, today announced the launch of IT-Leish, a rapid diagnostic test (RDT) for visceral leishmaniasis (VL). The company acquired the manufacturing rights for IT-Leish from Bio-Rad in September 2022 to prevent its withdrawal from the market1 and has since ensured the regulatory requirements have been met for reintroduction to the market.

  • Test reintroduced to the market following regulatory and performance validation for UKCA marking.
  • Launch supports World Health Organization’s strategic plan for the elimination of life-threatening neglected tropical disease.
IT Leish Product

IT-Leish is a high-performance, immuno-chromatographic RDT that is used for the diagnosis of VL, a life-threatening neglected tropical disease (NTD) transmitted by phlebotomine sandflies. Early VL diagnosis is a vital component of controlling the disease, which is considered fatal if not treated rapidly 2. IT-Leish is a trusted RDT, taking 20 minutes to generate results. It provides reliable and accurate confirmation of clinically suspected cases of VL to enable early diagnosis, reducing disease fatality.

In January 20233, the WHO announced the development of a strategic plan to review the current epidemiological situation in East Africa, with regional and country-level elimination targets for 2023-2027. As part of this and the WHO’s wider 2021-2030 road map for NTDs, plans will be drawn to ensure long-term and sustainable financing and the procurement of medical supplies, including first-line diagnostics. By harnessing its expertise in lateral flow development and manufacturing, GADx has ensured IT-Leish is fit for regulatory purposes and available on the market as UKCA marked to support these critical campaigns.

Emily Adams, Chief Impact Officer, GADx, commented: “As an impact-led organisation, GADx is committed to developing high quality and affordable diagnostic tests to provide diagnostic capabilities to low-resource areas, allowing treatment of infections to begin more quickly and help save lives. By acquiring the IT-Leish rapid diagnostic test and ensuring it remains accessible to the market, GADx is supporting the WHO’s road map for eliminating NTDs. This work is essential to our mission and vision.”

1.     Press release (30th September 2022): https://www.globalaccessdx.com/global-access-diagnostics-acquires-manufacturing-rights-for-it-leish-rapid-diagnostic-test-from-bio-rad-laboratories

2.     https://www.who.int/news-room/fact-sheets/detail/leishmaniasis

3.     https://www.who.int/news-room/events/detail/2023/01/24/default-calendar/stakeholders-meeting-for-the-development-of-a-strategic-plan-for-the-elimination-of-visceral-leishmaniasis-in-east-africa

Frequent testing is invaluable and so it is vital to find ways to drive down the cost of kits and increase production levels. As a social enterprise, GADx can transform this process because it ‘breaks the link’ of ‘having to make profit for shareholders’.

Paul Davis
Co-founder of Mologic and pioneer of lateral flow diagnostics.